Investigating the role of P311 in the hypertrophic scar. (41/85)

 (+info)

Occlusion regulates epidermal cytokine production and inhibits scar formation. (42/85)

Hypertrophic scars are a major clinical problem, yet there are few therapeutics available to prevent or treat scar formation. One of the oldest known and most effective treatments is occlusion with silicone gel. However, little is known about its mode of action. It is hypothesized that occlusion increases the hydration state of the epidermis, and that this affects the epidermal and dermal cell behavior. This study investigated this possibility. Using the rabbit hypertrophic scar model, we determined that occlusion increased the hydration state of the epidermis in a dose-dependent manner, and significantly reduced the scar hypertrophy. Quantitative reverse transcription-polymerase chain reaction and immunohistochemistry showed that occlusion altered keratinocyte behavior, including keratin expression. Furthermore, occlusion significantly decreased the epidermal expression of the profibrotic cytokine interleukin-1beta and increased the epidermal expression of the antifibrotic cytokine tumor necrosis factor alpha. These alterations in the epidermal gene expression resulted in concomitant changes in the expression of the transforming growth factor-beta family members by cells in the dermis, resulting in a decrease in profibrotic signaling within the dermis. In summary, the results of this study indicate that occlusive therapy was able to decrease dermal fibrosis by hydrating the epidermis and altering the pro- and antifibrotic signals produced following injury.  (+info)

Prosthodontist contribution in treating post-burn hypertrophic facial scars. (43/85)

 (+info)

Nonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation? (44/85)

 (+info)

Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. (45/85)

 (+info)

Influence of the human leukocyte antigen complex on the development of cutaneous fibrosis: an immunogenetic perspective. (46/85)

 (+info)

Standard guidelines of care: Keloids and hypertrophic scars. (47/85)

 (+info)

Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. (48/85)

 (+info)